Αρχική World News Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with... World News Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC Από Ogkologos - 9 Απριλίου, 2025 825 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Do Cancer Survivors Have To Be Positive All the Time? Letting... 10 Νοεμβρίου, 2021 Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of... 17 Σεπτεμβρίου, 2025 What to Know About Using Activated Charcoal During Cancer 21 Δεκεμβρίου, 2023 Pembrolizumab Demonstrates Robust and Durable Antitumour Activity in Patients with Previously... 13 Ιανουαρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Is That New Lump or Bump a Sarcoma? Taking on DNA repair to tackle cancer Wishes for a New Year! AI for early cancer detection: where are we now?